Indicatie
Hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia A (congenital factor VIII deficiency): with factor VIII inhibitors without factor VIII inhibitors who have: severe disease (FVIII < 1%) moderate disease (FVIII ? 1% and ? 5%) with severe bleeding phenotype. Hemlibra can be used in all age groups.
In andere landen
Dezelfde werkzame stoffen in andere registers, met hetzelfde merk eerst.
Nationale vermeldingen
De nationale registers waarin dit EU-geneesmiddel staat.